<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63765">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912937</url>
  </required_header>
  <id_info>
    <org_study_id>TP-1363</org_study_id>
    <nct_id>NCT01912937</nct_id>
  </id_info>
  <brief_title>Drug-coated Angioplasty Balloons for Subjects With Constriction or Blockage in the Leg Arteries, Specifically the Superficial Femoral or Popliteal Arteries: A Pharmacokinetic Study</brief_title>
  <acronym>PK</acronym>
  <official_title>Prospective, Non-Randomized, Single-Arm, Multi-Center, Pharmacokinetic Study for the Treatment of Subjects Presenting With De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using a Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Covidien</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Covidien</source>
  <oversight_info>
    <authority>New Zealand: Health and Disability Ethics Committees</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the pharmacokinetics of paclitaxel in the blood delivered from a paclitaxel
      coated percutaneous angioplasty balloon catheter as a result of treatment of de novo or
      restenotic lesion(s), occluded/stenotic or re-occluded/restenotic lesion(s).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Paclitaxel Levels</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of  paclitaxel concentration in the circulating blood immediately after last balloon deployment, 1, 4, 24 hours,  7, 14, 30, 60 days and 6 months (if applicable) post-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Events as a Safety Measure (Composite)</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Freedom from device and procedure-related death through 30 days post-procedure; and freedom from target limb major amputation and clinically-driven target lesion revascularization through 12 months post-procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurements of Pharmacokinetics variables: Cmax, Tmax, AUC</measure>
    <time_frame>(0-t) and half-life</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>DCB Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with the CVI Drug-coated Balloon (DCB)</intervention_name>
    <description>Treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)</description>
    <arm_group_label>DCB Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female greater than or equal to 18 years of age.

          -  Subjects with symptomatic leg ischemia, requiring treatment of the Superficial
             Femoral Artery (SFA) or popliteal artery.

        Exclusion Criteria:

          -  Pregnant or lactating females.

          -  Known intolerance to study medications, paclitaxel or contrast agents that in the
             opinion of the investigator cannot be adequately pre-treated.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Holden, MD</last_name>
      <phone>+ 64 9 307 4949</phone>
    </contact>
    <investigator>
      <last_name>Andrew Holden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>Percutaneous Transluminal Angioplasty</keyword>
  <keyword>Balloon Catheter</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>PAD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
